Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 29 | ICEECE2012 | Next issue

15th International & 14th European Congress of Endocrinology

Oral Communications

Pituitary Clinical I

ea0029oc1.1 | Pituitary Clinical I | ICEECE2012

Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study

Colao A. , Bronstein M. , Freda P. , Gu F. , Shen C. , Gadelha M. , Fleseriu M. , Hermosillo Resendiz K. , Ruffin M. , Chen Y. , Sheppard M.

Introduction: Using the criterion of GH<2.5 μg/l and normalized IGF1, response rates to currently available somatostatin analogues in medically-naïve patients with acromegaly are 20–25% after 12 m. The broader somatostatin receptor binding profile of pasireotide may potentially improve response rates. This randomized, double-blind 12-m study compared pasireotide LAR with octreotide LAR.Methods: Patients with acromegaly (GH>5 μ...

ea0029oc1.2 | Pituitary Clinical I | ICEECE2012

Patients with Cushing’s disease achieve normal urinary cortisol with LCI699, a potent 11β-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study

Bertagna X. , Pivonello R. , Fleseriu M. , Zhang Y. , Robinson P. , Taylor A. , Watson C. , Maldonado M. , Hamrahian A. , Boscaro M. , Biller B.

Introduction: The clinical features and complications of Cushing’s syndrome result from chronic excess of circulating cortisol, typically quantified by 24-h urinary free cortisol (UFC). LCI699 is a potent inhibitor of 11β-hydroxylase. Since 11β-hydroxylase catalyzes the final step of cortisol synthesis, LCI699 is a potential new treatment for all forms of Cushing’s syndrome.Methods: Adult patients with mild-to-severe Cushing’s di...

ea0029oc1.3 | Pituitary Clinical I | ICEECE2012

Efficacy and safety of long-term treatment with pegvisomant in acromegaly: Italian pegvisomant observational study (ACROSTUDY)

Bianchi A. , Grottoli S. , Bogazzi F. , Colao A. , Sicolo N. , Cannavo S. , Ghigo E. , De Marinis L. , Acrostudy Group Italian

ACROSTUDY is an international observational study to evaluate efficacy and safety of long-term treatment with pegvisomant (PEGA) in acromegaly. ACROSTUDY Italy was started in 2007 and we report data from the first 185 patients (93M, 92F, mean age, range, 49.9 y; 17–83.8 y) treated with PEGA (mean duration, range, 3.2 y, 0.1–8.5 y), from 24 centers, until 01/2010. Before and during PEGA, IGF1, GH-Ab, liver enzymes, metabolic parameters and pituitary MRI were assessed....

ea0029oc1.4 | Pituitary Clinical I | ICEECE2012

A multi-centre audit of the prevalence of cardiac valvulopathy in patients treated with dopamine agonists for hyperprolactinaemia

Drake W. , Stiles C. , Bevan J. , Steeds R.

Bromocriptine (BC) and cabergoline (CAB) are ergot-derived dopamine agonists (DAs) used for the treatment of hyperprolactinaemia. Recently, concern has been raised about a possible association between long-term DA use and cardiac valvular abnormalities. These concerns are largely derived from studies in patients with Parkinson’s disease receiving higher doses (typically CAB 3 mg/day vs 0.5–1 mg/week for hyperprolactinaemic patients). Studies in hyperprolactinaemic pa...

ea0029oc1.5 | Pituitary Clinical I | ICEECE2012

Initial hypothalamic involvement is the major risk factor for impaired prognosis and quality of life in childhood craniopharyngioma regardless of chosen treatment strategies: results of KRANIOPHARYNGEOM 2000

Muller H. , Gebhardt U. , Warmuth-Metz M. , Kortmann R. , Faldum A. , Pietsch T. , Gabriele C. , Sorensen N.

Hypothalamic obesity has major impact on prognosis and quality of life (QoL) in childhood craniopharyngioma (CP). The pathogenic relevance of initial hypothalamic involvement versus treatment-related hypothalamic lesions is a matter of controversy.One hundred and twenty patients were recruited prospectively during 2001 and 2007 and evaluated after 3 years of follow-up. Body mass index (BMI) and QoL at diagnosis and 36 mo after diagnosis were analyzed bas...

ea0029oc1.6 | Pituitary Clinical I | ICEECE2012

Normal weight adult patients with Prader–Willi syndrome are not protected from insulin resistance during treatment with GH: results from a 12 month prospective study

Jorgensen A. , Ueland T. , Sode-Carlsen R. , Schreiner T. , Rabben K. , Farholt S. , Hoybye C. , Christiansen J. , Bollerslev J.

Background: Diabetes mellitus is prevalent in adults with Prader–Willi syndrome (PWS), and GH therapy may deteriorate glucose balance.Design: We prospectively investigated effects of 12 months of GH treatment on body composition and insulin resistance in relation to BMI in forty-two adults, mean(±S.D.) age 28.5±6.7 years with genetically verified PWS. Three patients with known diabetes were excluded. Data from baseline and 1...